EUVIMEDEUVIMED entdecken
Crossref

Outcomes and Trends of Treatments in High‐Risk Differentiated Thyroid Cancer

Arash Abiri iD, Khodayar Goshtasbi, Sina J Torabi, Edward C Kuan, William B Armstrong, Tjoson Tjoa, Yarah M Haidar

Otolaryngology–Head and Neck Surgery · 2023

DOI: 10.1177/01945998221095720 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2023. Verfasst von Arash Abiri und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, University of California-Irvine, Orange, California, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Carcinoma, Papillary. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To analyze the variant‐specific survival benefits and usage patterns of standardized treatment combinations of surgery (S), radioactive iodine ablation (RAI), and thyroid‐stimulating hormone suppression therapy (THST) for high‐risk differentiated thyroid cancer. Study Design Retrospective cohort study.

Setting

National Cancer Database.

Methods

The 2004‐2017 National Cancer Database was queried for patients receiving definitive surgery for high‐risk papillary, follicular, or Hurthle cell thyroid cancer. Cox proportional hazards and Kaplan‐Meier analyses assessed for treatment‐associated survival.

Results

Of 21,076 cases, 18,214 underwent survival analysis with a mean ± SD age of 50.6 ± 17.1 years (71.3% female). When compared with surgery alone, S + RAI was associated with reduced mortality in papillary (hazard ratio [HR], 0.574; P < .001) and follicular (HR, 0.489; P = .004) thyroid cancer. S + RAI + THST was associated with reduced mortality in papillary (HR, 0.514; P < .001), follicular (HR, 0.602; P = .016), and Hurthle cell (HR, 0.504; P = .021) thyroid cancer. In papillary thyroid cancer, S + RAI (91.3%), S + THST (89.2%), and S + RAI + THST (92.7%) were associated with higher 5‐year overall survival rates than surgery (85.4%, all P < .001). Papillary thyroid cancer treatments involving THST were associated with higher 5‐year overall survival rates than corresponding regimens without THST (all P < .001). In follicular thyroid cancer, S + RAI (73.9%) and S + RAI + THST (78.7%) were associated with higher 5‐year overall survival rates than surgery (65.6%, all P < .05). In Hurthle cell thyroid cancer, S + RAI (66.5%) and S + RAI + THST (73.4%) were associated with higher 5‐year overall survival rates than surgery (53.7%, all P < .05). On linear regression, THST usage increased by 77.5% ( R 2 = 0.944, P < .001), while RAI usage declined by 11.3% ( R 2 = 0.320, P = .035).

Conclusions

High‐risk differentiated thyroid cancer exhibited varying susceptibilities to different treatment combinations depending on histology, with greatest responses to regimens that included RAI. Physician practices have trended toward decreased RAI and increased THST usage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsCarcinoma, PapillaryHumansFemaleAdultMiddle AgedAgedMaleThyroid Cancer, PapillaryIodine RadioisotopesTreatment OutcomeRetrospective StudiesThyroidectomyAdenoma, Oxyphilic

Stichwörter der Autor:innen

Hurthle cellfollicularhigh riskpapillarysurvivalthyroid cancertreatment

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, University of California-Irvine, Orange, California, USA.
  • Department of Neurological Surgery, University of California-Irvine, Orange, California, USA.

ORCID-Profile: Arash Abiri

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Abiri, A., Goshtasbi, K., Torabi, S. J., Kuan, E. C., Armstrong, W. B., Tjoa, T., & Haidar, Y. M. (2023). Outcomes and Trends of Treatments in High‐Risk Differentiated Thyroid Cancer. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1177/01945998221095720

Vancouver

Abiri A, Goshtasbi K, Torabi SJ, Kuan EC, Armstrong WB, Tjoa T, et al. Outcomes and Trends of Treatments in High‐Risk Differentiated Thyroid Cancer. Otolaryngology–Head and Neck Surgery. 2023. doi:10.1177/01945998221095720

BibTeX
@article{Abiri2023,
  author = {Abiri, Arash and Goshtasbi, Khodayar and Torabi, Sina J and Kuan, Edward C and Armstrong, William B and Tjoa, Tjoson and Haidar, Yarah M},
  title = {Outcomes and Trends of Treatments in High‐Risk Differentiated Thyroid Cancer},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2023},
  doi = {10.1177/01945998221095720}
}
Kostenlos starten →